Novartis has withdrawn Piqray (alpelisib) from the German market after failing to strike a reimbursement deal for the first-in-class advanced breast cancer drug, which was approved for use across Europe last year.
Meanwhile, the company said it has secured reimbursement agreements for Piqray in several other European countries and that efforts to land market access deals throughout the rest of the continent were in the early stages